Breast cancer claims the lives of approximately 670,000 people per year. According to data from the World Health Organization (WHO), breast cancer was the most prevalent form of cancer among women in 157 out of 185 countries in 2022. Each year, over 2 million women are diagnosed with breast cancer, highlighting the importance of early detection and the development of targeted treatments for this deadly disease. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for the early-stage treatment of breast cancer. This medication is to be used in combination with hormone therapy for patients with early-stage breast cancer, particularly those concerned about cancer recurrence. The FDA has approved ribociclib (Kisqali) in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative stage II and III early breast cancer at high risk of recurrence. Additionally, the FDA has approved the ribociclib and letrozole co-pack (Kisqali Femara Co-Pack) for the same indication. Kisqali functions as a selective cyclin-dependent kinase inhibitor, blocking proteins CDK4 and CDK6 to slow down cancer progression. The drug is administered orally as a pill for three weeks followed by a one-week break, to be continued over a three-year period. It can be taken with or without food, with a recommended daily dose of 400 mg.Kisqali Side Effects: Common side effects of Kisqali medication include a decrease in white blood cell count, known as neutropenia. Neutropenia is a condition characterized by low levels of neutrophils in the bloodstream, which are crucial for fighting infections in the body. Additionally, Kisqali may also cause liver problems and interstitial lung disease or pneumonitis. Recognizing Early Symptoms of Breast Cancer